Edition:
United Kingdom

Aytu BioScience Inc (AYTU.OQ)

AYTU.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
22 Jun 2018
Change (% chg)

$-0.02 (-6.47%)
Prev Close
$0.33
Open
$0.33
Day's High
$0.33
Day's Low
$0.31
Volume
30,696
Avg. Vol
549,103
52-wk High
$6.35
52-wk Low
$0.29

Chart for

About

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent... (more)
No analyst recommendations are available for .

Overall

Beta: 2.45
Market Cap(Mil.): $0.80
Shares Outstanding(Mil.): 0.20
Dividend: --
Yield (%): --

Financials

  AYTU.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -54.43 -- --
ROI: -175.66 2.00 14.38
ROE: -319.61 3.49 16.08

BRIEF-Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2

* BIGGER CAPITAL FUND L P REPORTS A 7.4 PERCENT PASSIVE STAKE IN AYTU BIOSCIENCE INC AS OF MARCH 2 - SEC FILING Source text: (http://bit.ly/2HiWvi8) Further company coverage:

08 Mar 2018

BRIEF-Aytu Bioscience Gets Market Registration For The Mioxsys System For Male Infertility In Mexico

* AYTU BIOSCIENCE RECEIVES MARKET REGISTRATION FOR THE MIOXSYS® SYSTEM FOR MALE INFERTILITY IN MEXICO Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Aytu Bioscience Announces Pricing Of $12 Mln Public Offering

* AYTU BIOSCIENCE ANNOUNCES PRICING OF $12,000,000 PUBLIC OFFERING

02 Mar 2018

BRIEF-Aytu BioScience Provides Update On The Continued Growth Of Natesto In The U.S.

* AYTU BIOSCIENCE PROVIDES UPDATE ON THE CONTINUED GROWTH OF NATESTO® IN THE U.S. Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Aytu Bioscience Q2 Revenue $1.1 Mln, An Increase Of 32 pct

* AYTU BIOSCIENCE INC - TOTAL REVENUE FOR Q2 WAS ABOUT $1.1 MILLION, AN INCREASE OF 32%

08 Feb 2018

Earnings vs. Estimates